CureDuchenne Ventures Backs Exonics Therapeutics

Newport Beach-based investment fund CureDuchenne Ventures, which is a subsidiary of nonprofit CureDuchenne, announced this morning that it has invested $5M in a seed funding round for Exonics Therapeutics, a biotech startup which is focused on gene editing technology for treating Duchenne muscular dystrophy. Exonics Therapeutics is based in Boston, with reesarch in Dallas. CureDuchenne said that Exonics is developing a gene editing technology which potentially would make a permanent correction of the mutation that causes Duchenne. The funding goes towards preclinical research. More information »